First Hawaiian Bank Purchases 526 Shares of Sanofi (NASDAQ:SNY)

First Hawaiian Bank raised its position in Sanofi (NASDAQ:SNYFree Report) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 127,772 shares of the company’s stock after purchasing an additional 526 shares during the quarter. First Hawaiian Bank’s holdings in Sanofi were worth $6,354,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Spire Wealth Management increased its holdings in Sanofi by 6.7% in the second quarter. Spire Wealth Management now owns 3,106 shares of the company’s stock worth $167,000 after purchasing an additional 194 shares in the last quarter. Sage Rhino Capital LLC boosted its position in shares of Sanofi by 2.8% during the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after buying an additional 240 shares during the last quarter. Gallacher Capital Management LLC lifted its holdings in Sanofi by 4.5% during the third quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock worth $307,000 after acquiring an additional 245 shares during the period. Buckingham Strategic Wealth LLC lifted its holdings in Sanofi by 5.4% during the second quarter. Buckingham Strategic Wealth LLC now owns 4,822 shares of the company’s stock worth $260,000 after acquiring an additional 246 shares during the period. Finally, Captrust Financial Advisors lifted its holdings in Sanofi by 0.9% during the third quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock worth $996,000 after acquiring an additional 246 shares during the period. 10.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on SNY shares. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Morgan Stanley started coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered Sanofi from an “overweight” rating to a “neutral” rating in a report on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average target price of $57.50.

Read Our Latest Stock Analysis on SNY

Sanofi Stock Performance

Shares of SNY traded up $0.20 during mid-day trading on Friday, hitting $48.29. The stock had a trading volume of 1,267,096 shares, compared to its average volume of 1,816,973. The firm has a market cap of $122.15 billion, a P/E ratio of 20.46, a PEG ratio of 1.78 and a beta of 0.61. The business has a fifty day moving average price of $48.75 and a 200-day moving average price of $49.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82.

Sanofi (NASDAQ:SNYGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. On average, equities research analysts expect that Sanofi will post 4.2 EPS for the current year.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Articles

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.